- Obese people feel more pain
- Breast-fed babies less likely to become angry and irritable adults
- Rheumatoid arthritis drug halts organ damage in inflammatory genetic disorder
- Both maternal and paternal age behind autism
- Loneliness in old age 'worse than smoking'
- Southampton Varsity identify key peptides that could lead to universal vaccine for influenza
New approach may help treat breast, prostate cancers
Washington, Feb 8 (ANI): Loyola University research team led by an Indian-origin researcher claims to have discovered a novel protein that will help in developing treatments for breast cancer, prostate cancer and enlarged hearts.
When activated, the protein called RSK is involved in cell survival, cell proliferation and cell enlargement.
These properties contribute towards cancer progression, heart enlargement and tumours associated with a genetic disease called Carney complex.
Loyola researchers have discovered that a regulatory protein binds to RSK. This regulatory protein effectively keeps RSK's activity in check.
Dr Tarun Patel and his team located the specific region of the regulatory protein that binds to RSK.
"The implications are widespread, and will also change textbooks for students," he added.
It's been known for years that Carney complex is associated with mutations that cause a deficiency of the regulatory protein that binds to RSK.
This would lead to activation of RSK in Carney complex patients and contribute to tumour growth.
Currently there are no drugs to specifically treat Carney complex.
Therefore, developing medications to inactivate RSK could prove to be an important new therapeutic approach for Carney complex patients.
The study is published in the Journal of Biological Chemistry. (ANI)
India the first choice; New Delhiâ??s reluctance led to approach other countries: Lanka.
New hope for Liver Cancer patients.
New Seven Wonders of the World â?? Recreating history.
New seven world wonders contest is not scientific: UNESCO.
Good News for the HIV patients, Will get insurance coverage.
|
|
|
|
|
|
Comments:








